Boston Scientific shares drop almost 4% after company warns cyberattack will impact 2026 results

Traders Union
All News
Stocks
Boston Scientific slides 3.76% today

Highlights

Boston Scientific experienced a cyberattack in August 2026 that disrupted operations and is likely to impact third quarter and full year results.
The company revised guidance, projecting it will not achieve previously stated 2026 sales growth and adjusted earnings per share targets.
Shares of Boston Scientific are in a bearish structure with very high probability of trading between $41.68 and $44.87 over the next five days.

Sales outlook slashed as business functions recover slowly post-attack

Boston Scientific faced a significant cyberattack in August 2026, which the company indicated in an SEC filing is likely to materially affect its financial results for the third quarter and full year. The attack disrupted key business functions, including distribution and sterilization, with some recovery of systems reported. Revised guidance has been issued, with the company stating it is unlikely to meet its previously issued sales growth and adjusted earnings per share targets for 2026.

Anton Kharitonov, expert at Traders Union, notes severe pressure on Boston Scientific after its August 2026 cyberattack disclosure. He highlights the strong breakdown below all key moving averages and the rare alignment of oversold oscillator signals, confirming deep seller control. Kharitonov is skeptical that a floor at $41.68 will hold for long. The company’s cut to guidance and operational disruptions increase risk for investors. "Given the technical and fundamental risks, I am unconvinced by any near-term rebound unless price regains the $44.87 threshold decisively."

Viktoras Karapetjanc, expert at Traders Union, sees the recent cyberattack as a catalyst for necessary operational improvements. He believes that, despite short-term disruption, the company’s fundamentals — strong market position and ability to issue revised guidance — showcase management's resilience. Karapetjanc expects investor sentiment to recover as systems are restored and execution normalizes. He remains constructive, emphasizing that adverse news can unlock new entry points. "Challenges aside, I see opportunity for those willing to back a turnaround story at attractive levels."

Parshwa Turakhiya, analyst, views Boston Scientific as caught in a sharp sentiment-driven selloff after its guidance downgrade. He highlights the extreme oversold readings on RSI, CCI, and Stochastic RSI, creating conditions for short-term tactical bounces. Turakhiya notes that volatility is elevated and recommends traders watch for reactions at $41.68. "I see short-term reversal setups emerging for nimble traders if the selling exhausts itself near support."

Bearish momentum intensifies with sellers dominant and oversold signals

Boston Scientific is trading well below its 20-day ($48.93), 50-day ($46.93), and 200-day ($66.23) moving averages, confirming seller pressure and a bearish structure for short, medium, and long-term trends. The nearest ceiling is $43.9, with a floor at $41.68 providing the next key support; the long-term trend alignment remains bearish. Momentum readings show weakness, as the Moving Average Convergence Divergence (MACD) points to sell and the Average Directional Index (ADX) remains neutral, signaling an absence of strong trend strength. The Relative Strength Index (RSI) at 38.54, Commodity Channel Index (CCI) at -139.65, and Stochastic RSI at 0 all indicate oversold conditions, while Bull/Bear Power (BBP) at -1.17 confirms that sellers currently dominate intraday dynamics and is also flagged as oversold. The Awesome Oscillator (AO) supports this negative tone. Boston Scientific opened with a downside gap of about $0.70 (1.56%) and is extending losses to $43.27, down $1.69 or 3.76% on the day and trading near the session low with intraday volatility at 0.91%. There is clear pressure after the open, as heavy selling is consistent with momentum and oscillator signals.

Earlier, analysts noted that Boston Scientific faced persistent downside risks amid technical headwinds and elevated uncertainty following the disclosure of a major cyberattack. The latest developments reinforce the bearish outlook, with the stock now projected to remain under pressure in the $41.68 to $44.87 trading range over the next five sessions.

Source of Data: BSX Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.